Polyphor AG

Swiss Biotech Association

Member
Claim / update listing

Polyphor is a clinical stage biopharmaceutical company focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics against Gram-negative bacteria, the Outer Membrane Protein Targeting Antibiotics (OMPTA).

https://www.polyphor.com/

Location

Hegenheimermattweg 125, 4123 Allschwil, Schweiz

Get Directions

Facts & figures

Type of organization

Public company
Year of foundation

1996
Number of employees in Switzerland

50-149

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

Limula SA

Limula SA is developing a platform technology to enable scale out of cell therapy manufacturing, directly at the point of care. We support companies at all stages of the life cycle of their therapies, from R&D to routine production.
La Tour-de-Peilz

Member

Laevoroc Oncology AG

Founded in 2019, Laevoroc is a privately-owned, Swiss oncology group of companies that leverages word-class technologies, our oncology expertise and extensive R&D and commercial experience to approach innovation in cancer therapeutics in a way that combines the pragmatic with the visionary.
Hünenberg

Member

Rowestil Consulting GmbH

Expertise in exploratory clinical drug/diagnostic development is available across a number of disease areas. Timing of input into the developmental strategy from regulatory and commercial perspectives is important in moving development programs towards success.
6318 Walchwil

Member